(ADCT) ADC Therapeutics - Ratings and Ratios

ADC Therapeutics SA (NYSE:ADCT) is a biotechnology company specializing in the development of antibody drug conjugate (ADC) therapies for hematologic malignancies and solid tumors. Its proprietary ADC technology platform combines monoclonal antibodies with cytotoxic payloads to target cancer cells while minimizing harm to healthy tissue. The companys lead product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed ADC approved by the FDA under accelerated approval and by the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have received two or more prior therapies. ZYNLONTA has shown significant clinical activity in this patient population, with a 48.3% complete response rate in the LOTIS-2 trial.

ADC Therapeutics is actively expanding ZYNLONTAs label through the LOTIS-5 Phase 3 trial, which is evaluating the drug as a second-line therapy for DLBCL, and the LOTIS-7 Phase 1b trial, investigating its use in combination with other agents. The company is also exploring ZYNLONTA in earlier lines of therapy for DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL). Beyond ZYNLONTA, the companys clinical-stage pipeline includes ADCT-602, a CD22-targeted ADC in a Phase 1/2 investigator-initiated trial for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). ADCT-601, targeting AXL, is being studied in sarcoma, pancreatic cancer, and non-small cell lung cancer (NSCLC), both as a single agent and in combination regimens.

The companys preclinical pipeline includes next-generation ADCs targeting Claudin-6, NaPi2b, PSMA, and undisclosed antigens, showcasing its commitment to innovation in ADC technology. ADC Therapeutics was founded in 2011 and is headquartered in Epalinges, Switzerland, with a focus on improving outcomes for cancer patients globally.

3-Month Forecast: Based on technical and fundamental data, ADCT is expected to face headwinds in the near term. The stock is trading below its 200-day SMA of 2.71, indicating bearish momentum. The 20-day and 50-day SMAs are converging near 1.61 and 1.76, respectively, suggesting limited upside. The ATR of 0.13 reflects reduced volatility, which may constrain significant price movements. On the fundamental side, the high P/B ratio of 2.58 could indicate overvaluation relative to book value. However, the companys focus on expanding its clinical pipeline and international market presence may offset some downside risks. Expect ADCT to trade in a narrow range with potential resistance at 2.00 and support near 1.50.